Capecitabine's Label Updated Under FDA Project Renewal Initiative Capecitabine's Label Updated Under FDA Project Renewal Initiative
Project Renewal is updating the labels of older oncology drugs to reflect current evidence.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Survival Benefit With Capecitabine Maintenance in Metastatic CRC Survival Benefit With Capecitabine Maintenance in Metastatic CRC
A new analysis reveals a significant reduction in the risk of death with capecitabine maintenance vs active monitoring. The study was published as a preprint and has not yet been peer reviewed.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 7, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Adjuvant Capecitabine for Early Breast Cancer Adjuvant Capecitabine for Early Breast Cancer
Could adjuvant treatment with capecitabine provide survival benefits in early breast cancer? A long-term follow-up of these patients provides insight.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. (Source: NHS Networks)
Source: NHS Networks - February 25, 2022 Category: UK Health Source Type: news

BioPlus Specialty Pharmacy Unveils “Hope Delivered in 24 Hours” for...
Nationwide specialty pharmacy commits to accelerated delivery of generic oncology medication, capecitabine; brings hope and faster time to treatment for patients, including those with metastatic colon...(PRWeb January 25, 2022)Read the full story at https://www.prweb.com/releases/bioplus_specialty_pharmacy_unveils_hope_delivered_in_24_hours_for_oncology_patients/prweb18437382.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 25, 2022 Category: Pharmaceuticals Source Type: news

Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer
Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

NICE does not recommend tucatinib for advanced breast cancer
NICE has published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread. (Source: NHS Networks)
Source: NHS Networks - October 27, 2021 Category: UK Health Source Type: news

Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer
In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 17, 2021 Category: Pharmaceuticals Source Type: news

Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC
First-line trifluridine/tipiracil plus bevacizumab offered a slight survival benefit over capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer in the TASCO1 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news